1303947-75-2

Upstream product

• 72778-00-8 (R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid 
• 117918-23-7 (R)-3-tert-butoxycarbonyl-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid 
• 62023-62-5 allophenylnorstatine 
• 62023-65-8 (2S,3S)-3-tert-butoxycarbonylamino-2-hydroxy-4-phenylbutanoic acid 
• 2900-27-8 (2S)-2-[(tert-butoxycarbonyl)amino]-2-phenylethanoic acid 
• 2935-35-5 (S)-2-phenylglycine 
• 1061337-79-8 KNI-10680 
• 56-12-2 4-amino-n-butyric acid 
• 1061338-75-7 (R)-N-(2,2-dimethylpropyl)-3-{(2S,3S)-3-[(2S)-2-amino-3,3-dimethylbutanoylamino]-2-hydroxy-4-phenylbutanoyl}-5,5-dimethyl-1,3-thiazolidine-4-carboxamide 
• 1061338-63-3 (R)-N-(2,2-dimethylpropyl)-3-[(2S,3S)-3-amino-2-hydroxy-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide 
• 1061338-51-9 (R)-N-(2,2-dimethylpropyl)-5,5-dimethyl-1,3-thiazolidine-4-carboxamide 
• 62965-35-9 N-tert-butyloxycarbonyl-L-tert-leucine 
• 20859-02-3 L-tert-Leucine 

Relevant academic research and scientific papers

Design and synthesis of several small-size HTLV-I protease inhibitors with different hydrophilicity profiles

The human T cell leukemia/lymphotropic virus type 1 (HTLV-I) is clinically associated with adult T cell leukemia/lymphoma, HTLV-I associated myelopathy/tropical spastic paraparesis, and a number of other chronic inflammatory diseases. To stop the replication of the virus, we developed highly potent tetrapeptidic HTLV-I protease inhibitors. In a recent X-ray crystallography study, several of our inhibitors could not form co-crystal complexes with the protease due to their high hydrophobicity. In the current study, we designed, synthesized and evaluated the HTLV-I protease inhibition potency of compounds with hydrophilic end-capping moieties with the aim of improving pharmaceutic and pharmacokinetic properties.